Monitor for initial safety and efficacy data from the Phase 1b HS trial, which could provide early read on soquelitinib's potential in Th17-driven diseases. The registrational Phase 3 PTCL trial remains the primary value driver.
Price Chart
Executive Summary
Corvus Pharmaceuticals announced the initiation of a Phase 1b trial of soquelitinib for hidradenitis suppurativa, a chronic inflammatory skin condition. This is a pipeline-expansion event for a clinical-stage biotech with no approved products and no financial data in the release.
Key Facts
- Phase 1b trial of soquelitinib for hidradenitis suppurativa has begun enrollment
- Trial will enroll up to 25 patients with moderate to severe disease
- Primary endpoint is safety and tolerability; key efficacy endpoint is HiSCR 50/75 at week 12
- Soquelitinib is also in a registrational Phase 3 for PTCL, Phase 2 for atopic dermatitis, and Phase 2 for ALPS
- Company plans to initiate a Phase 2 trial in asthma later this year
Financial Impact
No financial data provided; early-stage clinical trial with no revenue impact expected for years
Risk Factors
- Phase 1b trial is early-stage with small sample size; results may not be predictive of later-stage outcomes
- Hidradenitis suppurativa is a competitive market with existing biologic therapies
- Company has no approved products and relies on future capital raises to fund operations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372383 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | Press Release | $10.93 $10.90 | ▼ −0.27% | ▼ −1.01% | $10.45 (−4.39%) |
Aug 21, 2026 9w ago | Institutional Cluster | $14.46 $14.09 | ▼ −2.56% | ▼ −2.26% | $10.45 (−27.73%) |
Jul 22, 2026 13w ago | 8-K | $13.68 $13.07 | ▼ −4.46% | ▼ −4.56% | $10.45 (−23.61%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.60 $11.93 | ▲ +2.84% | ▲ +2.30% | $10.45 (−9.91%) |
May 14, 2026 23w ago | 8-K | $13.66 $12.31 | ▼ −9.85% | ▼ −8.62% | $10.45 (−23.47%) |
May 7, 2026 24w ago | 8-K | $15.55 $15.81 | ▲ +1.67% | ▲ +1.44% | $10.45 (−32.80%) |
Apr 24, 2026 26w ago | DEFA14A | $15.92 $15.62 | ▼ −1.88% | ▼ −1.40% | $10.45 (−34.36%) |
Apr 21, 2026 26w ago | Press Release | $17.14 $17.85 | ▲ +4.14% | ▲ +3.12% | $10.45 (−39.03%) |
Mar 12, 2026 32w ago | Press Release | $15.32 $15.72 | ▲ +2.61% | ▲ +1.59% | $10.45 (−31.79%) |
Mar 5, 2026 33w ago | Press Release | $15.80 $15.89 | ▲ +0.60% | ▼ −0.24% | $10.45 (−33.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers